PGDx signs licensing deal with Memorial Sloan Kettering Cancer Center - Technical.ly Baltimore

Sciences

Feb. 28, 2018 12:49 pm

PGDx signs licensing deal with Memorial Sloan Kettering Cancer Center

The deal gives Baltimore-based PGDx intellectual property to bolster its cancer tests.
Pipettes and test tubes.

Pipettes and test tubes.

(Photo by Flickr user Luca Volpi, used under a Creative Commons license)

Personal Genome Diagnostics is adding to its IP portfolio to further develop new kinds of cancer tests.

A licensing deal announced Wednesday gives the Canton-based company exclusive rights to develop and commercialize products based on a key discovery at Memorial Sloan Kettering Cancer Center in New York. Financial terms were not disclosed.

The two entities were both involved in research of a biomarker called tumor mutation status. This measures the number of mutations in a tumor. In a 2015 study published by Memorial Sloan Kettering researchers in the journal Science, patients with more mutations responded to a new form of cancer immunotherapy than those with a tumor with fewer mutations. It suggests that tests could indicate whether certain patients are good candidates for the drugs.

According to a statement from PGDx CEO Doug Ward, the new patents add to existing IP that the company has in the area.

“In 2016 we licensed co-exclusive rights to important intellectual property in this area from Johns Hopkins University and are now pleased to reinforce our IP portfolio by licensing MSK’s complementary patents,” Ward said. “We are confident that the combined patent estate adequately protects our extensive investment and development plans for our TMB-enabling tests.”

The company’s tests are based on work to analyze cancer at the genomic level that began at Johns Hopkins in 2010. It combines gene sequencing and algorithms, as well as new forms of testing. One such test would allow a biopsy to be taken from a blood sample.

The licensing deal comes a little more than a month after PGDx closed a $75 million Series B funding round, and said announced plans to develop the testing to be completed outside a lab. The company is also expanding to a second Baltimore office in Brewers Hill.

-30-
CONTRIBUTE TO THE
JOURNALISM FUND

Already a contributor? Sign in here
Connect with companies from the Technical.ly community
New call-to-action

Advertisement

Protenus cofounder Robert Lord is returning to JHU medical school, joining LionBird Ventures as partner

Chesapeake Digital Health Exchange aims to spur regional startup growth

emocha and University of Maryland School of Pharmacy join forces on medication reviews

SPONSORED

Baltimore

Technology is ever evolving — shouldn’t business education be, too?

Annapolis Junction, MD

Asymmetrik

FULL-STACK DEVELOPER

Apply Now

Annapolis Junction, MD

Asymmetrik

SOFTWARE ENGINEER

Apply Now

Annapolis Junction, MD

Asymmetrik

FRONT-END DEVELOPER

Apply Now

University of Maryland awarded $200M for flu vaccine research

MICA Game Lab and Shock Trauma are developing VR games for spinal injury patients

Baltimore-based Capsulomics wins first place at Patriot Boot Camp in Utah

SPONSORED

Baltimore

How independence fuels confidence and professional development at SmartLogic

Philadelphia, PA - Center City

Odessa

Sr. Project Manager – ERP Implementations

Apply Now

Philadelphia, PA - Center City

Odessa

Business Architect

Apply Now

Philadelphia, PA

Vistar Media

QA Engineer

Apply Now

Sign-up for daily news updates from Technical.ly Baltimore

Do NOT follow this link or you will be banned from the site!